Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE

Pharma Giants' Cost Trends: Taro vs. Evotec

__timestampEvotec SETaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201460118000179279000
Thursday, January 1, 201589690000186359000
Friday, January 1, 2016105953000171785000
Sunday, January 1, 2017175062000208136000
Monday, January 1, 2018263389000198405000
Tuesday, January 1, 2019313546000224169000
Wednesday, January 1, 2020375181000245044000
Friday, January 1, 2021466491000252314000
Saturday, January 1, 2022577383000268225000
Sunday, January 1, 2023606375000304629000
Monday, January 1, 2024324203000
Loading chart...

Igniting the spark of knowledge

Cost of Revenue Trends: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Taro Pharmaceutical Industries Ltd. and Evotec SE, two prominent players, have shown distinct trends in their cost of revenue from 2014 to 2023. Taro's cost of revenue has seen a steady increase, rising approximately 70% over the decade, peaking at 324 million in 2024. Meanwhile, Evotec SE has experienced a more dramatic surge, with costs escalating by over 900%, reaching 606 million in 2023. This stark contrast highlights Evotec's aggressive expansion strategy compared to Taro's more measured growth. The data for 2024 is missing for Evotec, leaving room for speculation on whether this trend will continue. As the pharmaceutical landscape shifts, these insights provide a window into the financial strategies of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025